ELQ-300 Prodrugs for Enhanced Delivery and Single-Dose Cure of Malaria

ELQ-300 is a preclinical candidate that targets the liver and blood stages of Plasmodium falciparum, as well as the forms that are crucial to transmission of disease: gametocytes, zygotes, and ookinetes. A significant obstacle to the clinical development of ELQ-300 is related to its physicochemical...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Antimicrob Agents Chemother
Päätekijät: Miley, Galen P., Pou, Sovitj, Winter, Rolf, Nilsen, Aaron, Li, Yuexin, Kelly, Jane X., Stickles, Allison M., Mather, Michael W., Forquer, Isaac P., Pershing, April M., White, Karen, Shackleford, David, Saunders, Jessica, Chen, Gong, Ting, Li-Min, Kim, Kami, Zakharov, Lev N., Donini, Cristina, Burrows, Jeremy N., Vaidya, Akhil B., Charman, Susan A., Riscoe, Michael K.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society for Microbiology 2015
Aiheet:
Experimental Therapeutics
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4538462/
https://ncbi.nlm.nih.gov/pubmed/26124159
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01183-15
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia